DualityBio will receive an up front and will be eligible for a contingent payment if BeiGene exercises its option, ~$1.3B in an additional fee upon achievement of development, regulatory, and commercial milestones along with royalties
BeiGene retains global clinical, manufacturing, and commercial rights to ADC therapy upon exercising its option while DualityBio will be responsible to continue preclinical research activities and support IND filing
The collaboration will advance both companies’ strengths to advance ADC therapies. In addition to developing 10+ novel product candidates that are currently in the preclinical stage, DualityBio has advanced four assets into global clinical studies
Ref: Businesswire | Image: BeiGene
Related News:- BeiGene’s Brukinsa (zanubrutinib) Receives the US FDA’s Approval for Chronic Lymphocytic Leukemia
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
